Senores Pharmaceuticals liquidity ratios

Per cent unless marked ×
Tap a line for its trendLast 12Mto Sep 2026FY26Mar 2026FY25Mar 2025
6.99×——
1.92×1.92×3.00×
1.71×1.71×2.77×
18.045.6105
355388482
Open the chart

From the company's filings with NSE and BSE (Ind-AS), consolidated. For information only, not investment advice.

SENORES₹1,214.00

Senores Pharmaceuticals Limited

· Pharma & Health
₹ CrorePeersSANOFIINNOVACAPMOREPENLABIOLCPFDCPGHLSANOFICONRORCHPHARMAMcap ₹5,590 Cr
ProfitabilityGrowthCreditLiquidityWorking CapitalYield AnalysisDuPont
Ratios — % unless marked ×
12 Months Ending
FY25
31/03/2025
FY26
31/03/2026
Last 12M
30/09/2026
Altman Z-Score (Other Equity as RE)——6.99
Current Ratio3.001.921.92
Quick Ratio2.771.711.71
Cash, Equiv & ST Investments105.445.618.0
Working Capital481.7388.4354.7
No consensus estimates → no Est columns. Click any row to chart it.
« ‹ › »Latest: FY26 · ConsolidatedFA Financial Analysis · alphave
Data & compliance. Descriptive financial information from official NSE/BSE filings — for information and education only, not investment advice, a recommendation, or a valuation. Standalone = parent entity; consolidated includes subsidiaries. Historical multiples pair each fiscal year's filed figures with that FY-end market close; the Current column uses the last close with the latest filed annuals. Figures are cross-verified via accounting identities and NSE×BSE agreement — XBRL cross-verified ✓ 95%.